Gritstone Oncology

$11.12 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Gritstone Oncology

Gritstone bio, Inc., formerly Gritstone Oncology, Inc., is a biotechnology company. The Company is focused on developing targeted immunotherapies for cancer and infectious disease. The Company's programs are built on two key pillars: Gritstone EDGE artificial intelligence platform, which enables the Company to identify antigens that can be recognized by the immune system; and a potent immunotherapy platform, which is engineered to deliver the selected antigens. Its pipeline include GRANITE, SLATE, BiSAb and CORAL. GRANITE is the Company's first oncology product candidate, which is a personalized neoantigen-based immunotherapy. SLATE utilizes the same neoantigen delivery system as GRANITE but contains a fixed set of neoantigens that are shared across a subset of cancer patients. The Company has a program focused on the development of bispecific antibody (BiSAb) therapeutics using highly tumor-specific antigens. CORAL is a second-generation vaccine against SARS-CoV-2.

Stock Analysis

last close $10.84
1-mo return 21.4%
3-mo return 27.5%
avg daily vol. 863.97T
52-week high 35.2
52-week low 2.86
market cap. $760M
forward pe -
annual div. -
roe -51.8%
ltg forecast -
dividend yield -
annual rev. $46M
inst own. 62.8%
baraka

Subscribe now for daily local and international financial news

Subscribe